Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients

HIV Medicine

Volumn 6, Issue 3, 2005, Pages 145-150

  Seminari, E ^a   Castagna, A ^a   Soldarini, A ^a   Galli, L ^a   Fusetti, G ^a   Dorigatti, F ^a   Hasson, H ^a   Danise, A ^a   Guffanti, M ^a   Lazzarin, A ^a   Rubinacci, A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiretroviral therapy; HIV infection; Osteopenia; Osteoprotegerin; RANKL

Indexed keywords

ALKALINE PHOSPHATASE; ANTIRETROVIRUS AGENT; CALCIUM; CREATININE; DEOXYPYRIDINOLINE; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VITAMIN D;

ADULT; AGE; ARTICLE; BODY MASS; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; BONE REMODELING; BONE TURNOVER; CELL ACTIVATION; CLINICAL EXAMINATION; CLINICAL OBSERVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; VITAMIN D DEFICIENCY; WORLD HEALTH ORGANIZATION;

ADULT; AGE FACTORS; ALKALINE PHOSPHATASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; BODY MASS INDEX; BONE DISEASES, METABOLIC; BONE REMODELING; CREATINE; CROSS-SECTIONAL STUDIES; FEMALE; GLYCOPROTEINS; HIV INFECTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TIME FACTORS; VITAMIN D DEFICIENCY;

EID: 21144439422     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00278.x     Document Type: Article

References (27)

1. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
2. Hernandez Quero J, Ortego Centeno N, Muñoz Torre M, Martinez Perez MA, Torres-Puchol JM. Alterations in bone turnover in HIV-positive patients. Infection 1993; 21: 220-222.
3. Aukrust P, Haug CJ, Ueland T et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999; 84: 145-150.
4. Lawal A, Engelson E, Wang J, Heymsfield SB, Kotler DP. Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy. AIDS 2001; 15: 278-280.
5. Serrano S, Mariñoso ML, Soriano JC et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone 1995; 16: 185-191.
6. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15: 703-709.
7. McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S. Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 2001; 74: 679-686.
8. Tebas P, Powderly G, Claxton S et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63-F67.
9. Huang JS, Rietschel P, Hadigan CM, Rosenthal DI, Grinspoon S. Increased abdominal visceral fat is associated with reduced bone density in HIV-infected men with lipodystrophy. AIDS 2001; 15: 975-982.
10. Ueland T, Bollerslev J, Godang K, Muller F, Froland S, Aukrust P. Increased serum osteoprotegerin disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685-690.
11. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15: 1823-1829.
12. Mondy K, Yarasheski K, Powderly GW et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. CID 2003; 36: 482-490.
13. Glesby MJ. Bone disorders in human immunodeficiency virus infection. CID 2003; 37 (Suppl. 2): S91-S95.
14. Hannon RA, Eastell R. Biochemical markers of bone turnover and fracture prediction. J Br Menopause Soc 2003; 9: 10-15.
15. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142: 5050-5055.
16. Black D, Duncan A, Robins SP. Quantitative analysis of pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 1988; 169: 197-203.
17. Fairfield WP, Finkelstein JS, Klibanski A, Grinspoon SK. Osteopenia in eugonadal immune deficiency syndrome wasting syndrome. J Clin Endocrinol Metab 2001; 86: 2020-2026.
18. Silva Santos AC, Lopes Crisostomo LM, Olavarria V, Brites C, Galvao-Castro B. Alterations in bone mineral metabolism in Brazilian HIV-infected patients. AIDS 2003; 17: 1578-1580.
19. Nacher M, Serrano S, Gonzalez A et al. Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS 2001; 15: 2239-2243.
20. Clements MR, Johnson L, Fraser DR. A new mechanism for induced vitamin D deficiency in calcium deprivation. Nature 1987; 325: 62-65.
21. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17: 513-520.
22. Tebas P, Yarasheski KE, Whyte M et al. Serum and urine markers of bone mineral metabolism in HIV infected patients taking protease inhibitor containing potent antiretroviral therapy. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, September 2000 [Abstract 029].
23. Vescini F, Borderi M, Buffa A et al. Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr 2003; 33: 405-407.
24. Yano K, Tsuda E, Washida N et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Mineral Res 1999; 14: 518-527.
25. Lacey DL, Timms E, Tan HL et al. Osteprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1988; 93: 165-176.
26. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277: 19247-19250.
27. Nielesen SP. The fallacy of BMD: a critical review of the diagnostic use of dual X-ray absorptiometry. Clin Rheumatol 2000; 19: 171-183.